Not provided
Not provided
Not provided
Not provided
The Medical Device (SmartPill) used in this project is no longer on the market
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Treatments efficacy in irritable bowel syndrome (IBS) patients is inconstant and predictive factors of their efficacy are needed. The role of dysbiosis in IBS is well-known. Another way to identify microbiota differences is to assess its metabolic activity. It has been demonstrated that colonic pH in IBS patients is lower than in healthy volunteers, reflecting a highest colonic fermentation. Colonic acidification is able to sensitize colonic mechano-receptors to distension. Microbiota profile is able to predict the response to a low Fermentable Oligo, Di, Monosaccharides And Polyols (FODMAPs) diet, but is not available in clinical routine.
The aim of our study is to assess the link between colonic fermentation (measured by colonic pH) and the efficacy of a low FODMAPs diet in IBS patients (measured by IBS severity scoring system (IBS-SSS)). We hypothesis that IBS patients with a lower colonic pH will have a better efficacy of the low FODMAPs diet. It might allow in the future personalized medicine.
50 IBS patients according to Rome IV criteria will be included in our study. All patients will have a measure of their colonic pH by wireless motility capsule. Patients will follow a low FODMAPs diet for 6 weeks after an education by a trained dietician. All participants will fill validated questionnaires before and after 6 weeks of low FODMAPs diet: IBS-SSS, Gastro Intestinal Quality of Life Index (GIQLI), Hospital Anxiety and Depression (HAD) scale. Microbiota, metabolomic and short chain fatty acid will be analysed before and after the intervention. The number of patients was calculated to assess the correlation between colonic pH and the variation of IBS-SSS before and after the intervention.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IBS patients | Experimental | Patients suffering from IBS according to Rome IV criteria |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low FODMAP diet | Dietary Supplement | After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet. |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between efficacy of the low FODMAP diet on severity and the colonic pH | Correlation between colonic pH (baseline) and the variation of IBS severity score (IBS-SSS). IBS-SSS is a score between 0 (no symptom) to 500 (highest symptom level). | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between efficacy of the low FODMAP diet on quality of life and the colonic pH | Correlation between colonic pH (baseline) and variation of the quality of life Index (GIQLI). GIQLI is a score between 0 (lowest quality of life) and 144 (best quality of life). | 6 weeks |
| Correlation between efficacy of the low FODMAP diet on stool frequency and the colonic pH |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chloé Melchior, MD, PhD | University Hospital, Rouen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rouen University Hospital | Rouen | 76000 | France |
upon request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| ID | Term |
|---|---|
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000092622 | FODMAP Diet |
| ID | Term |
|---|---|
| D000092724 | Elimination Diets |
| D004032 | Diet |
| D009747 | Nutritional Physiological Phenomena |
| D000066888 | Diet, Food, and Nutrition |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Correlation between colonic pH (baseline) and variation of the stool frequency |
| 6 weeks |
| Correlation between efficacy of the low FODMAP diet on stool consistency and the colonic pH | Correlation between colonic pH (baseline) and variation of the stool consistency (BSF) | 6 weeks |
| Correlation between efficacy of the low FODMAP diet on anxiety and the colonic pH | Correlation between colonic pH (baseline) and variation of anxiety (HAD). HAD anxiety is a scale comprised between 0 (no anxiety) and 21 (highest anxiety). | 6 weeks |
| Correlation between efficacy of the low FODMAP diet on depression and the colonic pH | Correlation between colonic pH (baseline) and variation of depression (HAD). HAD depression is a scale comprised between 0 (no depression) and 21 (highest depression). | 6 weeks |
| Correlation between short chain fatty acids and the colonic pH | Correlation between colonic pH (baseline) and variation of short chain fatty acids (in the stool) | 6 weeks |
| Correlation between metabolites and the colonic pH | Correlation between colonic pH (baseline) and variation of metabolites (in the stool). Among metabolites, short chain fatty acids, 28 biliary acids and lipopeptides (C12-GABA, C12-Glutamine, C14-Glutamine, C15-GABA, C16-Glutamate, C16-Glutamine, C18-GABA, C12:1-Alanine (Ala)-GABA, C12-Ala-GABA, C13-Ala-GABA, C14:1-Ala-GABA et C183OH-Glutamate-GABA) will be assessed. Metabolites will be also assessed by RMN spectroscopy that allow the assessment of a high ranges of different metabolites. | 6 weeks |
| Colonic pH according to small intestinal bacterial overgrowth | Comparison of colonic pH between patients with and without small intestinal bacterial overgrowth | baseline |
| Colonic pH according to fructose malabsorption | Comparison of colonic pH between patients with and without fructose malabsorption | baseline |
| Colonic pH according to visceral hypersensitivity | Comparison of colonic pH between patients with and without visceral hypersensitivity | Baseline |
| Colonic pH and fecal calprotectin | Correlation between colonic pH and fecal calprotectin | Baseline |
| Colonic pH and rectal pain threshold | Correlation between colonic pH and rectal pain threshold | Baseline |
| Correlation between baseline QOL and the colonic pH | Correlation between colonic pH and baseline GIQLI (quality of life Index) | Baseline |
| Correlation between baseline IBS severity score and colonic pH | Correlation between colonic pH and baseline IBS severity score (IBS-SSS) | Baseline |
| Correlation between baseline anxiety and colonic pH | Correlation between colonic pH and baseline anxiety (HAD) | Baseline |
| Correlation between baseline depression and colonic pH | Correlation between colonic pH and baseline depression (HAD) | Baseline |
| Correlation between baseline stool consistency and colonic pH | Correlation between baseline stool consistency (BSF) and colonic pH | Baseline |
| Correlation between baseline stool frequency and colonic pH | Correlation between baseline stool frequency and colonic pH | Baseline |
| D004066 | Digestive System Diseases |
| D010829 | Physiological Phenomena |